Tu Chao, Zhou Jianping, Yuan Lianwen
Department of Geriatric Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China.
Tumour Biol. 2016 May;37(5):5761-3. doi: 10.1007/s13277-016-4910-8. Epub 2016 Jan 27.
With great interest, we carefully read a meta-analysis entitled "MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies" in Tumor Biology (by Wu KP et al.), in which the investigators aimed to assess the association between MT1-MMP expression and prognosis of patients with various types of cancers by calculating the pooled hazard ratio (HR) with corresponding 95 % confidence interval (95 % CI). They have reached an important conclusion that MT1-MMP overexpression indicated an unfavorable overall survival (OS) in cancers and the pooled HR (95 % CI) was 2.46 (95 % CI 1.75-3.47). In addition, subgroup analysis showed the HRs (95 % CI) were 3.73 (95 % CI 2.67-5.21) and 2.46 (95 % CI 1.69-3.59) for MT1-MMP in lung cancer and gastric cancer, respectively. Before these results can be accepted, we would like to address several concerns related to this meta-analysis.
我们饶有兴趣地仔细阅读了发表于《肿瘤生物学》（作者：吴克平等）上的一篇名为“MT1-MMP并非癌症生存的良好预后指标：来自11项研究的证据”的荟萃分析。在该分析中，研究人员旨在通过计算合并风险比（HR）及相应的95%置信区间（95%CI），评估MT1-MMP表达与各类癌症患者预后之间的关联。他们得出了一个重要结论，即MT1-MMP过表达表明癌症患者的总生存期（OS）不佳，合并HR（95%CI）为2.46（95%CI 1.75 - 3.47）。此外，亚组分析显示，MT1-MMP在肺癌和胃癌中的HR（95%CI）分别为3.73（95%CI 2.67 - 5.21）和2.46（95%CI 1.69 - 3.59）。在接受这些结果之前，我们想提出几个与该荟萃分析相关的问题。
